The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Human growth hormone cannot be understood in isolation. It is the effector endpoint of a multi-level neuroendocrine axis that includes hypothalamic regulators, pituitary somatotrophs, hepatic IGF-1 production, and systemic feedback loops. Understanding the axis explains why secretagogues work, why pulsatile matters, and why exogenous HGH is pharmacologically different from stimulated endogenous GH.
The GH axis operates as follows: the hypothalamus produces growth hormone-releasing hormone (GHRH) — the primary stimulatory signal for GH release from pituitary somatotroph cells. It also produces somatostatin (SST) — the primary inhibitory signal. Pulsatile GH release results from the alternating dominance of GHRH and somatostatin: GHRH surges trigger GH pulses; somatostatin between pulses suppresses basal GH. The largest GH pulses occur 60-90 minutes after sleep onset during slow-wave sleep — which is why disrupted sleep architectures profoundly affect GH output and why many GH optimization protocols emphasize sleep quality. Ghrelin (and ghrelin-mimetic compounds — GHRPs, ipamorelin, MK-677) provides a third stimulatory pathway via the GH secretagogue receptor (GHSR), acting synergistically with GHRH to amplify GH pulse amplitude. Growth hormone released from the pituitary circulates to the liver, where it binds GH receptors and stimulates the production and release of IGF-1 (Insulin-like Growth Factor 1). IGF-1 mediates most of GH's tissue-building and metabolic effects, providing a long-acting signal (half-life 12-15 hours) compared to GH's brief plasma half-life of 20-30 minutes. IGF-1 feeds back negatively on the hypothalamus and pituitary to suppress further GH release — completing the feedback loop.
THE CENTRAL TENSION
Exogenous HGH injection replaces a hormone that the body normally secretes in large nocturnal pulses with what is effectively a pharmacological dose of continuous exposure. A pituitary somatotroph cell releasing GH in response to GHRH produces a large, brief pulse that is mostly cleared from circulation within 30 minutes. A subcutaneous HGH injection produces a slower, broader pharmacokinetic profile that sustains GH elevation for 4-6 hours — a fundamentally different exposure pattern. For confirmed GH-deficient adults, this replacement produces profound and well-documented clinical benefits regardless of the non-physiological delivery pattern. For eugonadal adults with normal GH secretion: exogenous HGH adds to existing GH output, producing supraphysiological IGF-1 levels that drive both the desired body composition effects and the dose-dependent adverse effects — edema, arthralgia, carpal tunnel, glucose intolerance. The entire secretagogue category (sermorelin, CJC-1295, ipamorelin, MK-677) was developed to exploit the fact that preserving pulsatile GH release through stimulation of endogenous production avoids the continuous-exposure pharmacokinetics of direct HGH injection, potentially offering more physiological profiles at lower risk — and at substantially lower cost.
Adult GHD treatment is weight-independent and titrated based on IGF-1 response, not body weight — a critical difference from pediatric dosing which uses weight-based calculations. Starting dose: 0.2-0.4 mg/day (approximately 0.6-1.2 IU/day) for adults under 60; 0.1-0.2 mg/day for adults over 60 (age-dependent sensitivity to side effects). Titration: increase by 0.1-0.2 mg every 4-8 weeks based on IGF-1 response and clinical tolerance. Target: IGF-1 in the normal range for age and sex — typically 0 to +2 SDS. Treatment is dose-adjusted to avoid supraphysiological IGF-1 levels (>+2 SDS). Women on oral estrogen require higher GH doses than men or women on transdermal estrogen due to oral estrogen's first-pass effect reducing hepatic IGF-1 production.
IGF-1 (somatomedin-C) is the primary laboratory monitoring parameter during GHD treatment. IGF-1 correlates with GH action on the liver and reflects the integrated GH exposure over 24 hours better than any random GH measurement. Target during treatment: IGF-1 0 to +2 SDS (standard deviation scores) for the patient's age and sex. IGF-1 >+2 SDS indicates overtreatment — dose should be reduced. IGF-1 below the lower normal limit suggests insufficient replacement. The timing of IGF-1 measurement: at trough for daily injections (morning, before daily dose); any time for once-weekly formulations given stable levels. Important limitation: IGF-1 SDS varies by assay — absolute values are lab-specific; SDS relative to age/sex norms is the clinically meaningful number.
IGF-1 IS THE SINGLE MOST IMPORTANT MONITORING PARAMETER FOR ALL HGH USE
Whether using pharmaceutical somatropin for confirmed GHD or community-source HGH for body composition, IGF-1 is the primary safety and dosing parameter. IGF-1 below the age/sex normal range: insufficient dose or poor product quality. IGF-1 in mid-normal range (0 to +2 SDS): appropriate for GHD replacement. IGF-1 above +2 SDS (supraphysiological): overtreatment risk — dose should be reduced; persistent supraphysiological IGF-1 drives side effects (edema, arthralgia, glucose intolerance) and raises the long-term cancer concern. Community users who use HGH without IGF-1 monitoring are operating blind to the most important safety parameter for this compound.
Test
Timing
Target / Action
IGF-1 (somatomedin-C)
At initiation; 4-8 weeks after each dose change; stable: every 6 months
0 to +2 SDS for age/sex; >+2 SDS = reduce dose
Fasting glucose / HbA1c
At initiation; 6 months; annually
Normal range; GH mildly antagonizes insulin; monitor for glucose intolerance especially in pre-diabetic patients
Lipid panel
At initiation; 12 months
LDL should decrease on appropriate GHD treatment; if worsening, reassess dose
Bone density (DXA)
At initiation; 2 years; every 2-3 years thereafter
Spine and hip BMD; significant improvements expected with adequate replacement
Quality of life questionnaire (QoL-AGHDA)
At initiation; 12 months; annually
Standardized assessment; QoL improvement is a primary treatment goal
Thyroid function (TSH, FT4)
At initiation; periodically
GHD often co-exists with other pituitary deficiencies; GH treatment can unmask central hypothyroidism — TSH monitoring important
Cortisol (if relevant)
At initiation if adrenal insufficiency risk
GH can reduce cortisol by affecting cortisol-cortisone conversion — if patient on hydrocortisone for AI, may need dose adjustment
Fundoscopy
If papilledema or visual symptoms
Intracranial hypertension is rare but more common in pediatric patients; ophthalmology referral if symptoms develop
GH binds the GH receptor (GHR) — a class I cytokine receptor that dimerizes upon GH binding and activates JAK2 (Janus kinase 2), which phosphorylates STAT5b (Signal Transducer and Activator of Transcription 5b). The JAK2-STAT5b signaling cascade is the primary pathway driving GH's transcriptional effects. STAT5b activation drives gene transcription in liver (primarily IGF-1 production), muscle, bone, adipose tissue, and immune cells. Additional GH signaling pathways: MAPK (mitogen-activated protein kinase) — cell growth and differentiation; PI3K (phosphoinositide 3-kinase) — metabolic effects and insulin signaling. The insulin-antagonistic effect of GH: GH acutely stimulates lipolysis in adipose tissue (releasing free fatty acids) and reduces glucose uptake in peripheral tissues — creating a mild insulin-antagonist state that underlies the glucose metabolism concerns at supraphysiological doses.
Most of GH's tissue-building effects are mediated by IGF-1, produced primarily by the liver under GH stimulation. IGF-1 binds IGF-1R (a receptor tyrosine kinase similar to the insulin receptor) on target tissues. Key IGF-1 actions: stimulates protein synthesis in skeletal muscle; promotes bone mineralization and growth plate activity in children; inhibits protein catabolism (anti-proteolytic); stimulates cell proliferation and survival across multiple tissue types; enhances immune cell function. The GH-independent tissue IGF-1: muscle and other tissues also produce autocrine/paracrine IGF-1 independent of liver-derived IGF-1 — this local IGF-1 production is relevant to the discussion of GH's effects in muscle specifically.
In GH-deficient adults, somatropin replacement produces documented effects on body composition that are among the most robust in endocrinology: reduction in visceral and trunk fat (the most consistent effect; fat cells express GH receptors; lipolysis stimulated; fat oxidation increased); increase in lean body mass (protein synthesis; muscle anabolism via IGF-1); bone density improvement; improvement in lipid profile (HDL↑, LDL↓, triglycerides↓); improvement in exercise capacity; improvement in quality of life and mood. These effects are the reason GH replacement is Grade A evidence-based treatment in confirmed GHD. They are also the reason the compound is misused for body composition purposes — the same mechanisms operate in eugonadal adults, but the risk-benefit calculation is profoundly different.
Adult GHD is not diagnosed by a low random GH measurement — basal GH levels are frequently undetectable even in healthy people outside of secretory pulses. Diagnosis requires provocative GH stimulation testing: insulin tolerance test (ITT) — considered the gold standard; regular insulin administered IV to induce hypoglycemia (blood glucose <40 mg/dL); peak GH measured at 0, 30, 60, 90 minutes; threshold varies by assay: typically <3 ng/mL on modern chemiluminescent assays. GHRH + arginine test: often used when ITT is contraindicated (cardiac disease, epilepsy, elderly); peak GH threshold varies by BMI (<9 ng/mL for BMI <25; <4 ng/mL for BMI 25-30; <4 ng/mL for BMI >30). Additional criteria: IGF-1 below -2 SDS for age/sex norms; plus appropriate clinical context (pituitary pathology history, symptoms, three or more pituitary hormone deficiencies in which case peak GH threshold is lower). Two stimulation tests are required unless the patient has three or more proven pituitary deficiencies and an appropriately low IGF-1. This diagnostic process is the critical difference between legitimate medical GHD treatment and community HGH use — most community users have not undergone stimulation testing and are not confirmed GH-deficient.
The evidence base for somatropin replacement in confirmed adult GHD is among the strongest in endocrinology. The KIMS (Kabi International Metabolic Study) and HypoCCS (Hypopituitary Control and Complications Study) registries provide the largest long-term safety and efficacy databases — tens of thousands of patient-years of somatropin treatment data. Key findings: Trunk fat reduction: consistently documented across all major RCTs; meta-analyses confirm approximately 2-4% absolute trunk fat reduction vs placebo. Lean mass increase: approximately 1-3 kg lean mass gain in RCTs. Bone density: significant improvement in lumbar spine and total hip BMD in 2-year trials; continued improvement to 7-10 years in registry data. Quality of life: significant improvement on standardized questionnaires (QoL-AGHDA); effect size comparable to treatment of hypothyroidism or hypoadrenalism. Lipid profile: HDL increases, LDL decreases consistently. Mortality: The KIMS data suggests normalized mortality with long-term somatropin therapy in GHD — low untreated GHD is associated with increased cardiovascular mortality that appears corrected by treatment.
foresiGHt Phase 3 (n=259 adults with GHD; ages 23-80; DBRPC + open-label active comparator; 38 weeks): once-weekly lonapegsomatropin (TransCon hGH, Skytrofa) vs daily somatropin vs placebo. Results: Lonapegsomatropin was statistically superior to placebo for trunk fat reduction (primary endpoint) and lean mass increase (key secondary endpoint). Lonapegsomatropin was non-inferior and numerically comparable to daily somatropin for the same body composition endpoints. Safety was equivalent to daily somatropin with no study drug discontinuations. This trial established the first once-weekly formulation approved for adult GHD in July 2025 — representing a significant adherence advance for a condition where daily injection compliance is a documented barrier to treatment.
Brand / Compound
Formulation
Approved for Adults
Key Feature
Genotropin (Pfizer)
Daily SubQ; multi-dose pen device; lyophilized
GHD adults
Widely used; two-chamber cartridge (powder + diluent merged on use)
Humatrope (Eli Lilly)
Daily SubQ; cartridge system
GHD adults
Standard daily somatropin; cartridge system
Norditropin (Novo Nordisk)
Daily SubQ; pre-filled FlexPro pen
GHD adults
Pre-filled pen; ready to use; no reconstitution
Nutropin AQ (Genentech)
Daily SubQ; pen device
GHD adults
Aqueous formulation; no reconstitution
Omnitrope (Sandoz)
Daily SubQ; biosimilar somatropin
GHD adults
Lower cost; first approved GH biosimilar in the US
Serostim (EMD Serono)
Daily SubQ; HIV wasting indication
HIV-associated wasting (adults); higher doses
FDA-approved for HIV wasting; highest prescribed doses of any approved indication
Zorbtive (EMD Serono)
Daily SubQ; short bowel syndrome
Short bowel syndrome; up to 4 weeks
Highest approved doses; up to 0.1 mg/kg/day for short-term use
Sogroya (somapacitan, Novo)
Once-weekly SubQ
GHD adults (first once-weekly approval)
Albumin-binding technology enables weekly dosing; GH equivalent to daily via albumin half-life extension
Skytrofa (lonapegsomatropin, Ascendis)
Once-weekly SubQ
GHD adults (July 2025); pediatric GHD
TransCon prodrug technology; releases unmodified somatropin slowly; July 2025 adult indication approval; foresiGHt trial basis
Community 'generic somatropin'
Daily SubQ; powder vials from gray market
Not FDA-approved; varying quality
'Blue tops,' 'black tops,' 'grey tops,' etc.; the most counterfeited injectable in community use; see Section 8
This is the most pharmacologically important distinction in the entire GH chapter — and the key to understanding why secretagogues and exogenous HGH are not equivalent.
Endogenous GH is secreted in large pulses — particularly during slow-wave sleep. A healthy young man may produce 5-10 GH pulses per day; the largest pulses occur 60-90 minutes after sleep onset and can produce serum GH peaks of 10-30 ng/mL before falling back to near-undetectable basal levels within 30-60 minutes. This pulsatile pattern matters for several reasons: (1) The GH receptor shows greater sensitivity and downstream signaling response to pulsatile exposure than continuous exposure — high-amplitude pulses activate JAK2-STAT5b more efficiently than lower-amplitude continuous exposure at the same total daily GH dose. (2) Pulsatile GH preserves GH receptor sensitivity — continuous GH exposure (as produced by large exogenous doses) causes GH receptor downregulation, reducing tissue responsiveness over time. (3) IGF-1 production peaks follow GH pulses with a delay — the liver's IGF-1 output is optimized for pulsatile GH input. (4) The insulin-antagonist effect of GH is concentrated during pulses; pulsatile GH allows insulin sensitivity to recover between pulses, minimizing glucose metabolism impairment. Exogenous HGH injection (SubQ) produces a more continuous pharmacokinetic profile: serum GH rises over 2-4 hours, peaks at 3-6 hours post-injection, and remains elevated for 8-12 hours at typical doses. This is substantially different from a physiological GH pulse in both amplitude pattern and duration.
The practical implications: at replacement doses in GHD patients (0.2-0.5 mg/day), the continuous-profile issue is less clinically significant because the total GH delivered is relatively small and the patient is replacing a deficiency. At performance or anti-aging doses (1-4+ IU/day), the more continuous profile, combined with higher total GH, drives IGF-1 to supraphysiological levels, maintains ongoing glucose metabolism impairment, and may contribute to GH receptor downregulation. The secretagogue advantage: compounds that stimulate endogenous GH (GHRH analogues like sermorelin and tesamorelin; GHRP/ghrelin mimetics like ipamorelin, GHRP-2, GHRP-6; and MK-677) produce GH pulses via the endogenous pituitary machinery — preserving the pulsatile pattern, maintaining negative feedback regulation (preventing IGF-1 from going supraphysiological), and costing substantially less than pharmaceutical HGH.
At appropriately targeted GHD replacement doses, the adverse effect profile is well-characterized and manageable. The most common adverse effects — concentrated during dose escalation: peripheral edema (fluid retention; typically ankles, feet, hands; resolves with dose adjustment); arthralgia and myalgia (joint and muscle pain; fluid-related; dose-dependent); carpal tunnel syndrome (fluid retention in the carpal tunnel; can be symptomatic at higher doses or in susceptible individuals); headache (in some patients, particularly early in treatment). These effects are dose-dependent, more common at higher doses, and typically resolve with dose reduction. They are substantially more common at community performance doses (1-4 IU/day) than at GHD replacement doses (0.2-0.5 mg/day = approximately 0.6-1.5 IU/day).
GH is a counter-regulatory hormone for insulin — it antagonizes insulin action in peripheral tissues and promotes hepatic glucose output. At physiological GHD replacement doses, this effect is modest and not clinically significant in most patients. However: in pre-diabetic patients or those with insulin resistance, even replacement doses can impair glucose tolerance; HbA1c monitoring at initiation and 6-12 months is required; patients on insulin for diabetes require careful monitoring and potential dose adjustment when starting GH. At supraphysiological community doses, insulin resistance is a significant and dose-dependent concern — users of performance HGH doses (3-6 IU/day) have meaningfully elevated glucose and insulin levels, and some develop frank type 2 diabetes or impaired fasting glucose. This risk is compounded when HGH is co-administered with androgens or other insulin-antagonistic compounds.
IGF-1 promotes cell proliferation and survival. High IGF-1 has been epidemiologically associated with increased risk of several cancers (colorectal, breast, prostate, lung) in population studies. GH stimulates IGF-1. This raises the theoretical question: does HGH use increase cancer risk? The evidence from long-term registries: KIMS and HypoCCS databases covering tens of thousands of GHD patients treated for up to 15+ years show no increase in cancer incidence with somatropin treatment at physiological replacement doses targeting IGF-1 within the normal range. The cancer risk concern is specifically associated with supraphysiological IGF-1 levels (>+2 SDS persistently) — not with physiological IGF-1 levels achieved with appropriate GHD treatment. The practical implication: IGF-1 monitoring and dose adjustment to keep IGF-1 within the normal range is not just a dosing parameter — it is the primary cancer risk mitigation strategy for HGH use of any duration.
ACTIVE MALIGNANCY — ABSOLUTE CONTRAINDICATION
HGH is absolutely contraindicated in patients with active malignancy of any type. GH and IGF-1 promote cell growth and survival — in cancer cells as in normal cells. Active cancer combined with exogenous HGH represents the most serious contraindication in this chapter. This applies equally to pharmaceutical GHD replacement and community HGH use. After successful cancer treatment, resumption of GHD therapy requires oncologist consultation — the benefit-risk calculation for GHD patients who have had cancer is complex and individualized. For community users: any personal history of cancer, or family history of GH-responsive malignancies (colorectal, prostate, breast), warrants careful consideration and physician consultation before any HGH use.
The KIMS (Pharmacia International Metabolic Study) and HypoCCS (Eli Lilly) patient registries contain the largest long-term safety datasets for somatropin in adults with GHD. Key long-term findings: no increase in overall cancer incidence vs age-matched general population; no increase in pituitary tumor recurrence; improvement in cardiovascular risk markers (lipids, body composition, glucose) sustained over time; bone density improvement maintained. A systematic review published in 2024 confirmed: somatropin at physiological replacement doses does not increase all-cause cancer mortality in GHD adults. The important caveat: all registry data applies to physiological replacement doses in confirmed GHD patients with IGF-1 monitored within normal limits. The long-term safety of supraphysiological community HGH use is not established by these registries.
HGH is the most frequently counterfeited injectable compound in the research chemical and performance enhancement community. Understanding why HGH fakes are so prevalent and how to detect them is the most practically important safety information for community users.
The challenge of HGH counterfeiting: somatropin is a 191-amino acid polypeptide with a molecular weight of approximately 22 kDa. It is difficult and expensive to manufacture correctly — requiring recombinant expression systems, purification, lyophilization, and quality control steps that legitimate pharmaceutical manufacturers invest heavily in. Generic 'somatropin' manufactured in non-GMP facilities (primarily in China) and sold as 'blue tops,' 'grey tops,' 'black tops,' 'green tops,' etc. varies widely in actual content. Common counterfeiting strategies: kits containing little to no actual somatropin but instead fragments, peptides, or other proteins that give false positive results on standard ELISA tests; kits containing primarily HCG (which activates growth-related pathways and can give some anabolic signals but is not somatropin); kits that are underdosed (containing 2-4 IU per vial instead of the labeled 10 IU); genuine somatropin from unauthorized sources at variable quality.
The serum GH test — the primary community quality check: the most widely used community verification method is to inject 10 IU of the HGH product and measure serum GH levels 2-3 hours post-injection (roughly the peak). A genuine 10 IU injection should produce serum GH levels of 30-50+ ng/mL in a fasting, rested individual. HGH below 5 ng/mL after a 10 IU injection is highly suggestive of a counterfeit or severely underdosed product. The limitation: this test requires a lab test, costs money, and is often not performed. The IGF-1 test: in addition to the acute GH serum test, monitoring IGF-1 after 4-8 weeks of consistent use is the practical ongoing quality check — if IGF-1 is not rising appropriately during use, the product is suspect. The IEF (isoelectric focusing) test: academic/pharmaceutical laboratories can test GH products for isoform purity — genuine recombinant somatropin should consist primarily of the 22 kDa isoform; contaminated or degraded products show aberrant isoform profiles. Community labs occasionally offer this service.
Product Type
Description
Community Name
Quality Signal
Pharmaceutical somatropin (FDA-approved)
Branded rhGH from major manufacturers (Pfizer, Novo Nordisk, Lilly, Sandoz, Genentech)
Genotropin, Norditropin, Omnitrope, etc.
Most reliable; chain of custody intact; cold chain maintained; most expensive
Gray market genuine somatropin
Pharmaceutical-grade somatropin from international pharmacies or diverted product; genuine somatropin but outside FDA supply chain
Serostim (diverted HIV indication), Hygetropin (Chinese licensed), Jintropin (Chinese licensed)
Variable; genuine products at lower cost; cold chain integrity unknown; legal gray area
Chinese gray market 'kits'
Non-GMP manufacture; highly variable content; labeled somatropin may contain little actual GH
'Blue tops,' 'grey tops,' 'black tops,' 'red tops,' 'yellow tops'
Highly variable 20-90% of labeled dose in legitimate testing; some batches contain no somatropin; IEF test and serum GH test recommended
Peptide fragments — not somatropin
Small peptide fragments (e.g., GH 176-191 / AOD-9604) labeled as HGH
'Fat burning peptides,' 'GH fragment'
NOT somatropin; does not raise IGF-1; different mechanism; entirely different compound — see AOD-9604 chapter
HCG-based fakes
HCG sold as HGH; HCG ELISA tests and some GH tests cross-react; gives some anabolic signal
Often sold as cheap 'HGH kits'
Will not raise IGF-1; serum GH after injection will be minimal; ELISA test distinguishes HCG from GH
For the community user seeking GH optimization, the most important strategic question is: exogenous HGH or a secretagogue that stimulates endogenous production?
Feature
Exogenous HGH (Somatropin)
GH Secretagogues (Sermorelin, CJC+Ipa, MK-677, etc.)
GH source
Exogenous; injected pharmaceutical protein
Endogenous; stimulates pituitary to release its own GH
Pulsatile pattern
No — produces more continuous pharmacokinetic profile
Yes — activates endogenous pulsatile GH release machinery
IGF-1 response
Can drive IGF-1 supraphysiological at community doses
Self-limiting: pituitary feedback prevents supraphysiological IGF-1
Pituitary function
Suppresses GH axis with prolonged use (negative feedback via IGF-1 and GH)
Maintains and in some contexts restores pituitary GH secretion capacity
Somatostatin sensitivity
Bypassed — GH delivered regardless of somatostatin tone
Works within somatostatin feedback — cannot overcome high somatostatin
Cost
High: pharmaceutical HGH is among the most expensive hormones; gray market substantial discount but quality concern
Generally lower cost; MK-677 oral; peptide secretagogues much cheaper than pharmaceutical HGH
WADA status
S2 — absolute ban; GH isoform + biomarker detection methods
Varies: GHRH analogues (S2); MK-677 (S2); some GHRPs (S2) — check current list
Efficacy in GHD
Gold standard replacement; superior for confirmed deficiency
Requires functional pituitary somatotrophs; not adequate for severe GHD where pituitary is damaged
Efficacy in eugonadal adults
Dose-dependent body composition effects; higher dose = more side effects
Modest GH optimization; ceiling effect limits IGF-1 elevation; generally lower side effects
Active malignancy
Absolute contraindication
Same contraindication applies to all GH-elevating compounds
Community HGH use falls broadly into three categories with different dose ranges: (1) GHD replacement (confirmed hypogonadal users or those treating diagnosed GHD): 0.2-0.5 mg/day (0.6-1.5 IU/day) — lowest dose range; titrated to bring IGF-1 to normal range; should be physician-supervised; this is the dose range supported by all the clinical safety data. (2) Anti-aging / longevity: 0.5-1.5 IU/day (0.17-0.5 mg/day) — attempting to restore GH/IGF-1 to youthful-adult levels in older individuals with age-related GH decline; rationale is to address the physiological age-related decline in GH secretion; IGF-1 monitoring essential. (3) Performance / body composition: 2-6+ IU/day (0.67-2+ mg/day) — supraphysiological range; body composition effects more pronounced; adverse effects (edema, glucose intolerance, arthralgia) more common; IGF-1 monitoring essential; this range is not supported by clinical safety data in confirmed GHD.
Community Context
Typical Dose
Protocol Notes
IGF-1 Target
Anti-aging / GH optimization (non-GHD)
1-2 IU/day SubQ
AM injection preferred (circadian); 5 days on/2 days off common convention to allow GH axis partial recovery
Upper half of normal range for age (~+0.5 to +1.5 SDS); not supraphysiological
Performance / body composition
2-4 IU/day SubQ, often split into 2 daily doses
Split into 2 injections (AM + PM) to smooth pharmacokinetics; 6 months on / 2-3 months off cycle common
Upper normal to mildly supraphysiological (target: +1.5 SDS — do not exceed +2 SDS)
Female users
Generally 50-75% of male dose
Women are more sensitive to HGH; start lower; titrate to IGF-1
Same targets — women often reach higher IGF-1 per IU dose
Stacking with IGF-1 LR3
Not recommended without extensive HGH experience
IGF-1 LR3 is a separate compound — exogenous IGF-1 LR3 + HGH creates additive IGF-1 receptor stimulation with amplified side effects
Monitor both endogenous IGF-1 and assess IGF-1 receptor activation symptoms
Glucose management during HGH
GH antagonizes insulin — take HGH away from carbohydrate meals
Fasting or low-carb context for injection; do not inject within 2 hours of high-carb meal
HbA1c at baseline; check at 3 months during performance use
Somatropin is on the WADA Prohibited List as S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — an absolute ban in competition and out-of-competition. Detection methodology: the GH isoform differential immunoassay — endogenous GH consists of multiple molecular isoforms (the 22 kDa isoform predominating at approximately 70%, with 20 kDa, glycosylated variants, and others); recombinant somatropin is almost exclusively the 22 kDa isoform; after exogenous HGH administration, the 22 kDa/non-22 kDa ratio changes detectably because the exogenous 22 kDa HGH suppresses endogenous pulsatile secretion of the other isoforms. This ratio returns toward normal within 24-72 hours of the last injection. The GH biomarker method: serum IGF-1 and P-III-NP (procollagen type III N-terminal propeptide, a marker of GH action on collagen synthesis) — elevated above normal limits provides longer detection windows (days to weeks depending on the extent of use). The combination of isoform and biomarker methods: WADA now uses both in parallel, extending effective detection. For competitive athletes: the detection window for the isoform method is 24-72 hours; the biomarker method extends this to potentially 2-3 weeks with consistent use. Any HGH use represents a WADA S2 ban — there is no threshold; the isoform ratio deviation from normal is sufficient for a positive finding.
All branded FDA-approved somatropin products contain the same active molecule (somatropin, 191 amino acids, identical to pituitary GH). However, the manufacturing process, purity, sterility, cold chain, and dosing accuracy differ substantially between pharmaceutical manufacturers and gray market suppliers. The fake HGH problem — documented contamination, underdosing, and substitution with non-GH compounds — makes source quality the most important practical variable in community HGH use. The IEF test and serum GH test are the primary community verification methods.
Secretagogues (sermorelin, CJC-1295, ipamorelin, GHRP-2/6, MK-677) and exogenous HGH both raise serum GH and IGF-1, but they work fundamentally differently. Secretagogues stimulate pituitary GH production — endogenous, pulsatile, self-regulated by negative feedback. Exogenous HGH delivers GH directly — bypassing the pituitary, producing a non-pulsatile pharmacokinetic profile, and suppressing the endogenous GH axis via negative feedback. These are not equivalent interventions. For confirmed GHD with pituitary damage, secretagogues are insufficient — only exogenous HGH replaces the missing hormone. For GH optimization in a person with an intact pituitary, secretagogues maintain pulsatile physiology and have a safety advantage.
GH produces its anabolic effects primarily via IGF-1. IGF-1 has a ceiling effect for muscle protein synthesis — there is a plateau above which additional IGF-1 does not produce additional anabolism. Supraphysiological HGH doses (>4 IU/day) drive IGF-1 to levels where additional protein synthesis benefit is marginal, while the adverse effects (edema, arthralgia, glucose intolerance, theoretical long-term cancer risk) continue to scale with dose. The body composition effects of HGH are primarily on fat mass reduction (via lipolysis) and lean mass increase — at performance doses the lean mass increase is real but smaller than many community users expect, and is largely due to water-associated lean mass (intramuscular glycogen and water retention) rather than contractile protein.
An IGF-1 of 400 ng/mL might be appropriate for a 25-year-old (whose age-sex reference range extends to 400+ ng/mL) but would represent significant overtreatment in a 50-year-old (whose age-sex reference range maximum might be 250-300 ng/mL). IGF-1 must always be interpreted as an SDS (standard deviation score) relative to age and sex norms — not as an absolute number. IGF-1 SDS >+2 represents supraphysiological levels for the patient's age and is the threshold for dose reduction, regardless of the absolute number.
Molitch ME, et al. (2011). Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 96(6):1587-1609. [The primary Endocrine Society guideline for adult GHD diagnosis and treatment; diagnostic criteria, dosing, monitoring, safety — the clinical standard.]
Aversa LS, Cuboni D, Grottoli S, Ghigo E, Gasco V. (2024). A 2024 Update on Growth Hormone Deficiency Syndrome in Adults: From Guidelines to Real Life. Journal of Clinical Medicine. 13(20). [Most current 2024 update on adult GHD management including once-weekly formulations, long-term safety registry data.]
foresiGHt Phase 3 trial (Ascendis Pharma). (2024-2025). Lonapegsomatropin vs placebo and daily somatropin in adult GHD; n=259; ages 23-80; 38 weeks; trunk fat reduction and lean mass increase primary endpoints; lonapegsomatropin superior to placebo, non-inferior to daily somatropin. Basis for FDA approval July 2025 (Skytrofa for adult GHD). [Most current adult GHD clinical evidence; once-weekly formulation Phase 3 data.]
KIMS (Pfizer International Metabolic Study) and HypoCCS (Eli Lilly). Long-term safety and efficacy registry data; tens of thousands of patient-years; no increase in cancer incidence at physiological replacement doses; bone density improvement sustained; QoL improvement maintained. [The primary long-term safety evidence base for somatropin in adult GHD.]
HGH is the most comprehensively evidenced hormone in this book for its medical indication — and the compound with the most significant quality assurance crisis in community use. The gap between pharmaceutical and gray market access has created a market where most community HGH is of unknown quality.
The honest summary: somatropin replacement in confirmed adult GHD is one of the most evidence-based interventions in endocrinology. The benefits — reduced visceral fat, improved lean mass, better bone density, improved lipid profile, improved quality of life, normalized mortality — are documented across decades of registry data and multiple Grade A RCTs including the July 2025 Skytrofa approval. The monitoring protocol is well-defined. The cancer risk at physiological replacement doses is not elevated. For confirmed GHD: somatropin is appropriate, evidence-based, and among the most impactful treatments available. For community use without confirmed GHD: the risk-benefit calculation depends entirely on source quality, dose selection, and IGF-1 monitoring rigor. Gray market HGH quality is the single greatest practical risk for community users — not the pharmacology of authentic somatropin, but the near-certain quality variability of unregulated supply chains. A community user who confirms their source quality via serum GH testing, monitors IGF-1 every 3-4 months, targets IGF-1 within the normal range, has no active malignancy or malignancy history, and uses doses below 2 IU/day is operating within a risk framework that is meaningfully different from unmonitored supraphysiological dosing.
— End of HGH / Somatropin —
THE PEPTIDE BIBLE | HGH / Somatropin | For Research & Educational Purposes Only
HGH / Somatropin: 191-amino acid polypeptide; identical to pituitary-derived GH; multiple FDA-approved brands (Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Zorbtive). Once-weekly: Sogroya (somapacitan), Skytrofa (lonapegsomatropin — adult GHD July 2025 approval). GH AXIS: GHRH (stimulatory) + somatostatin (inhibitory) from hypothalamus; ghrelin/GHRP pathway synergistic; pituitary somatotrophs release GH in large nocturnal pulses; GH → liver → IGF-1 (primary mediator, t1/2 12-15h); IGF-1 → negative feedback. PULSATILE vs CONTINUOUS: endogenous GH = large brief nocturnal pulses; exogenous SubQ HGH = broader, more continuous profile 4-8h; secretagogues preserve pulsatile pattern. MECHANISM: GHR → JAK2-STAT5b; MAPK; PI3K; insulin antagonism (lipolysis ↑, peripheral glucose uptake ↓). IGF-1 → IGF-1R (RTK); protein synthesis ↑; anti-proteolytic; cell proliferation. ADULT GHD DIAGNOSIS: peak GH <3-9 ng/mL on stimulation test (ITT or GHRH+arginine); IGF-1 <-2 SDS; symptoms. EVIDENCE (Grade A): KIMS and HypoCCS registries; multiple RCTs; trunk fat ↓, lean mass ↑, bone density ↑, HDL ↑, LDL ↓, QoL ↑, normalized mortality; no cancer risk increase at physiological doses. SKYTROFA (July 2025): FDA approval for adult GHD; once-weekly; foresiGHt Phase 3 (n=259; ages 23-80; 38wks); superior to placebo; equivalent to daily somatropin; major adherence advance. MONITORING: IGF-1 (primary; target 0 to +2 SDS for age/sex); fasting glucose/HbA1c; lipids; DXA; QoL questionnaire; thyroid; fundoscopy if symptoms. ACTIVE MALIGNANCY: absolute contraindication. CANCER CONCERN: supraphysiological IGF-1 (>+2 SDS) = dose reduce; physiological replacement = no cancer increase (registry data). FAKE HGH: most counterfeited injectable in community use; 'blue tops,' 'grey tops' etc. highly variable quality; serum GH test after 10 IU = primary community verification (expect >30 ng/mL); IEF isoform test available. ADVERSE EFFECTS: edema; arthralgia/myalgia; carpal tunnel (all dose-dependent, fluid-related); glucose intolerance/insulin resistance (dose-dependent); intracranial hypertension (rare). COMMUNITY DOSING: GHD replacement 0.2-0.5 mg/day (0.6-1.5 IU); anti-aging 1-2 IU/day; performance 2-4 IU/day. IGF-1 monitoring every 3-4 months mandatory. vs SECRETAGOGUES: exogenous HGH = non-pulsatile, suppresses axis, required for pituitary GHD; secretagogues = pulsatile, preserves axis, self-limiting IGF-1, lower cost, adequate for intact pituitary optimization. WADA: S2 absolute ban; isoform differential immunoassay (24-72hr window) + biomarker method (days-weeks).
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.